Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

De Andrés RAuthor

Share

Incidence of cardiovascular events and changes in the estimated risk and treatment of familial hypercholesterolemia: the SAFEHEART registry

Publicated to:REVISTA ESPANOLA DE CARDIOLOGIA. 73 (10): 828-834 - 2020-10-01 73(10), DOI: 10.1016/j.recesp.2019.10.013

Authors: Pérez de Isla L; Arroyo-Olivares R; Alonso R; Muñiz-Grijalvo O; Díaz-Díaz JL; Zambón D; Fuentes F; Mata N; Piedecausa M; Mañas MD; Sánchez Muñoz-Torrero JF; Miramontes-González JP; de Andrés R; Mauri M; Aguado R; Brea Á; Cepeda JM; Vidal-Pardo JI; Martínez-Faedo C; Barba MÁ; Argüeso R; Ruiz-Pérez E; Michán A; Arrieta F; Riestra Fernández M; Pérez L; Pinilla JM; Díaz-Soto G; Pintó X; Padró T; Badimón L; Mata P; Perez-Corral B; Almagro F; Arroyo R; Isla LPd; Saltijeral A; Mosquera D; Casañas M; Carbayo J

Affiliations

Abstract

© 2019 Sociedad Española de Cardiología Introduction and objectives: The SAFEHEART study was designed to analyze the situation of familial heterozygous hypercholesterolemia (FHH) and improve knowledge of this disease in Spain. Our objective was to determine the incidence rate of cardiovascular events, the estimated risk of developing an event and its modification, the use of lipid-lowering treatment, and the achievement of low-density lipoprotein cholesterol targets in patients with FHH. Methods: SAFEHEART is a prospective, open, multicenter, nationwide cohort study, with long-term protocol-based follow-up in a population of individuals with molecularly-characterized FHH. We analyzed patients older than 18 years with complete follow-up. Results: We included 2648 patients with FHH. The median follow-up was 6.6 (4.8-9.7) years. The overall incidence rate of cardiovascular events was 1.3 events/100 patient-years. After the follow-up, the 10-year estimated risk of developing a cardiovascular event was reduced from 1.6% to 1.3% (P < .001). In the last follow-up, 20.6% and 22.2% of the patients in primary and secondary prevention achieved low-density lipoprotein cholesterol values < 100 mg/dL and < 70 mg/dL, respectively. Conclusions: This study was performed in the largest population of patients with FHH in Spain. We identified the incidence rate of cardiovascular events, the estimated risk of developing a cardiovascular event and its modification, the achievement of low-density lipoprotein cholesterol targets, and the therapeutic management in this population. Although the cardiovascular risk of FHH is high, appropriate treatment reduces the likelihood of an event. Clinical trial registration: http://www.clinicaltrials.gov. Identifier: NCT02693548.

Keywords